ERBB2 and breast cancer: Although the samples were taken from an area where the exposure to depleted uranium is a risk, the incidence of co-expression of both p53 and HER-2/neu markers does not differ from similar cancer samples in areas that have not been exposed to depleted uranium, though, the greater immunoexpression of Her-2/neu in breast cancer in this population with risk for DU exposure, compared with findings on other populations not at risk, requires further investigation as it may reflect the possible role of DU in the induction or acceleration of network signaling between different Her-2 receptors.